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Non-clinical studies are necessary at each stage of the development of oncology
drugs. Many experimental cancer models have been developed to investigate car-
cinogenesis, cancer progression, metastasis, and other aspects in cancer biology
and these models turned out to be useful in the efficacy evaluation and the
safety prediction of oncology drugs. While the diversity and the degree of
engagement in genetic changes in the initiation of cancer cell growth and pro-
gression are widely accepted, it has become increasingly clear that the roles of
host cells, tissue microenvironment, and the immune system also play important
roles in cancer. Therefore, the methods used to develop oncology drugs should
continuously be revised based on the advances in our understanding of cancer.
In this review, we extensively summarize the effective use of those models, their
advantages and disadvantages, ranges to be evaluated and limitations of the
models currently used for the development and for the evaluation of oncology
drugs.
Progress of Cancer Biology is Closely Linked to Oncology
Drug Development
T he history of the development of oncology drugs, so-calledchemotherapeutic agents, is closely associated with the
progress of the biological understanding of cancer. Based on
the concept that cancer cells are capable of unlimited prolifera-
tion, substances that inhibit DNA replication or cell division
have been used as drugs for cancer treatment for a long period,
since the 1950s. Although the concept has remained unchanged
to the present day,(1) the discovery of cancer cell-specific
metabolic pathways has led to the development of antimetabo-
lites.(2) After the discovery of cancer cell-specific molecular and
cellular mechanisms that are essential for the survival and
growth of cancer cells, therapeutic drugs targeting these mecha-
nisms, so-called molecular targeted drugs, started to be devel-
oped.(3) Research into viral oncogenesis, started in the 1960s,
led to the discovery of oncogenes,(4) and research into the
genetic backgrounds of cancers led to the discovery of tumor
suppressor genes.(5) In the course of such studies, it also became
apparent that cancer is caused by genetic abnormalities such as
mutations, deletions, duplications, and translocations.(6–9)
Molecular targeted cancer drugs appeared in the 1990s;(10) can-
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cer was considered a disease characterized by abnormal differen-
tiation, and the efficacy of differentiation-inducing agents was
demonstrated.(11,12) Furthermore, it was shown that a solid tumor
tissue consists of cancer and host cells such as vascular cells,
fibroblasts, and cells in the immune system and that these host
cells are essential for tumor growth. Drugs targeting the function
of these host cells and their interactions with cancer cells were
proven to be effective.(13) Based on these findings, it has been
thought that regulatory mechanisms for the entire organism are
involved in the action of oncology drugs that regulate the
immune system.(14)
Significance of Non-Clinical Studies in Efficacy Evaluation
and Safety Prediction
Non-clinical studies are necessary at each stage of the develop-
ment of oncology drugs. Particularly, the efficacy and the
safety of a drug must be examined and evaluated before under-
taking any clinical study of the drug. Types of non-clinical
studies and how critical they are vary depending on the types
and mechanisms of action of oncology drugs. Non-clinical
studies required to develop drugs targeting cancer–host interac-
tions differ markedly from those on substances having direct
killing effects on cancer cells. Many experimental cancer mod-
els (animal models, ex vivo models, and in vitro models) have
been developed to investigate carcinogenesis, cancer progres-
sion, metastasis, and other aspects in cancer biology. These
models turned out to be useful in the efficacy evaluation and
the safety prediction of oncology drugs. The present review
summarizes the effective use of those models, their advantages
and disadvantages, ranges to be evaluated, and limitations of
the models used in non-clinical study.
Evaluation of Oncology Drugs Using Experimental Animal
Models
Two classes of experimental animal models for human can-
cers are currently used for the evaluation of oncology drugs:
transplantation models and autochthonous cancer models.
Transplantation models have been playing an important role
in the non-clinical evaluation of oncology drugs. They are
generally categorized into two types, namely xenograft mod-
els using human cancer cells and orthograft models using
murine cancer cells. There has been some debate that the
efficacy evaluation of oncology drugs in transplantation mod-
els might not be adequate for predicting the clinical efficacy
or the types of cancer for which the drug could be effective.
As autochthonous cancer models, chemical carcinogen-
induced models were first established and the subsequent
technological progress in gene manipulation allowed research-
ers to produce models harboring the genetic mutations of
human cancer. Although a number of technical issues regard-
ing the ability to maximize the utility of these models need
to be addressed, such as their usability, reproducibility, and
throughput compared with transplantation models, autochtho-
nous cancer models clearly show some promise. In Table 1,
we summarize the characteristics of those experimental can-
cer models used to evaluate the efficacy of oncology drugs in
non-clinical studies.
Transplantation cancer models. In general, the s.c. (hetero-
topic) transplantation models with cancer cell lines have been
used, and the efficacies of oncology drug response are evalu-
ated based on tumor size. These models are particularly useful
when a drug has a marked antiproliferative effect on cancer
cells. It is also easy to access tumor tissue samples from these
models for subsequent pharmacodynamic evaluations. Despite
such clear advantages, these models may not reflect the actual
characteristics of the cancer microenvironment because the s.c.
tissue is “heterotopic” for most cancer cells. In this context,
orthotopic transplantation models may reproduce the cancer
microenvironment more faithfully, although their utility caused
by species differences should be considered. To analyze metas-
tasis dissemination of cancer cells, experimental metastasis
models have been considered as useful for evaluating drug
efficacy in the process after the invasion of cancer cells from
the primary tumor into the nearby blood vessel. Although these
models have clear advantage in their usability and repro-
ducibility, they cannot reproduce the entire step before the
extravasation of cancer cells and may not accurately represent
actual metastases by injecting a substantial number of cancer
cells into the blood vessel. In this regard, spontaneous metasta-
sis models have been considered to reflect the process of the
metastasis of cancer cells more accurately than the heterotopic
or orthotopic transplantations. Despite the clear advantages of
these models, only a limited number of cancer cell lines are
available and the results of experiments often vary. In addition
to the above transplantation cancer models with cancer cell
lines, patient-derived xenograft models have been considered
as emerging animal models recapitulating the clinical condition
of individual cancer patients, and therefore attracted much
attention on precision treatment.(15–17)
Autochthonous cancer models. There are two major types of
autochthonous cancer models, carcinogen-induced models and
gene-engineered mouse (GEM) models. Of these, GEM models
have been regarded as a better choice for testing drug efficacy,
because the drug effects can be evaluated on autochthonous
cancer cells induced by gene mutations resembling human can-
cer. As summarized in Table 2, there are several pros and cons
to using autochthonous cancer models for drug efficacy tests in
non-clinical studies. In particular, the timing of tumor occur-
rence and tissue specificity are often the major concerns of
carcinogen-induced models and conventional knockout ⁄ trans-
genic mice. To overcome these issues, conditional gene knock-
out or gene expression technology provide us with the
opportunity to use GEM models that more closely represent
the pathology of human cancers. In addition to the above tech-
nical difficulties, the administrative challenges, such as mainte-
nance of mouse strains to acquire a sufficient number of mice
as well as the characters of each mouse model, including the
latency and incidence of tumor and other relevant issues, need
to be considered before undertaking efficacy studies testing
oncology drugs in GEM models. Nevertheless, new technolo-
gies, such as in vivo imaging methods for small animals, have
been introduced as powerful tools for quantitative evaluation
of cancer occurrence and subsequent growth in GEM models.
In Table 3, GEM models developing tumors induced by
genetic mutations found in corresponding human cancers are
summarized.
Spontaneous cancer models using companion animals. Even in
companion animals, such as dogs and cats, the incidence of
cancer has been increasing, likely due to their life extension
together with genetic factors. In fact, cancer has become the
leading cause of death among those companion animals. In
particular, it has been known that the mortality from cancer is
reported to be 47% (based on the report by the Veterinary
Cancer Society, http://www.vetcancersociety.org/members/) in
large breed dogs aged 10 years or more. Therefore, the estab-
lishment of early diagnosis methods and the development of
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therapeutic drugs for cancer in companion animals is being
actively pursued in the USA and Europe. Considering the
pathology of cancer in large breed dogs seems to be similar to
those in humans,(68) the utility of spontaneous cancer in large
breed dogs for testing new oncology drugs has already been
initiated in the USA and Europe.(69) In Japan, the leading
cause of death in dogs is also cancer with a mortality of 54%
(“The Ten Leading Causes of Death in Dogs and Cats”
reported by the Animal Insurance System Japan Animal Club),
which is much higher than the mortality rate of other diseases
such as heart disease (17%). Given these circumstances, stud-
ies for developing methods for the diagnosis and treatment of
cancer in dogs have been actively initiated. Based on the
results of these studies, the Japanese Society of Clinical
Veterinary Medicine have been discussing the significance of
cancer models using companion animals in non-clinical studies
for developing oncology drugs as well as preparing for the
establishment of relevant administrative and management sys-
tems for its application.
Evaluation of Oncology Drugs that Directly Target Cancer
Cells
The efforts of oncology drug development originally concen-
trated on the production of drugs that directly target the prolif-
eration or metabolic properties of cancer cells. Along with
discovery of oncogenic driver genes, development of molecu-
lar targeted drugs has been highlighted, which directly pinpoint
signal transduction pathways involving those driver genes, as
well as the protein degradation systems, epigenome, and meta-
bolic systems of cancer cells. As molecular targeted drugs, tyr-
osine kinase inhibitors (TKI), multi-targeted kinase inhibitors
(MTKI), and drugs that target molecular mechanisms for cell
cycle regulation and others have been successfully developed.
Although the classical anticancer chemotherapeutic drugs also
show cytotoxicity by attacking specific intracellular molecules,
the term “molecular targeted drug” in this report is defined as
a drug that has been developed through primary identification
of a molecule or a signaling pathway as a therapeutic target,
which is highly activated or deregulated in cancer cells.
Table 4 summarizes the pros and cons for evaluating molecu-
lar targeted drugs in non-clinical cancer models. The results
produced by the use of these models have been included in the
application of new drugs; the models believed to be essential.
Tyrosine kinase inhibitors and other kinase inhibitors. Tyro-
sine kinase inhibitors include epidermal growth factor receptor
inhibitors (gefitinib, erlotinib, lapatinib, and afatinib), human
epidermal growth factor receptor 2 inhibitors (lapatinib and
afatinib), anaplastic lymphoma kinase inhibitors (crizotinib,
ceritinib, and alectinib), BCR-ABL inhibitors (imatinib, dasa-
tinib, nilotinib, ponatinib, and bosutinib), a KIT inhibitor (ima-
tinib), SRC inhibitors (dasatinib and bosutinib), a JAK
inhibitor (ruxolitinib), a Bruton’s tyrosine kinase inhibitor
(ibrutinib), and a dual kinase MEK inhibitor (trametinib).
There are several other kinase inhibitors, including BRAF inhi-
bitors (vemurafenib and dabrafenib), a phosphatidylinositol-3
kinase inhibitor (idelalisib), and mammalian target of rapamy-
cin inhibitors (temsirolimus and everolimus). In addition, drugs
that target p38, AKT, p70S6 kinase, insulin-like growth factor
1 receptor, platelet-derived growth factor receptor (PDGFR),
fibroblast growth factor receptor (FGFR), MET, ROS 1, and
RET are currently being developed. For evaluating the effica-
Table 2. Characters of genetically engineered mouse models
Mutation type Conventional mutation
Conditional mutation
Mutation induction NA Viral (e.g. adex-Cre)
Tissue-specific (e.g. GFAP-
Cre, FABP-Cre)
Induced (e.g. R26-CreERT2,
Tyr-CreERT2)
Generation of embryonic
lethal knockout animals
Not available Available Available Available
Tissue specificity Uncontrollable
Tumors generated are not
necessarily present in the
same tissues as those in
humans
Induce tissue-specific ⁄ local
mutation
Tumors can be generated
in the same tissues as
those in humans
Induce selective mutation
at a cellular level
Reproduce cancer
initiating cells
Inducible selective
mutation at a tissue or
cellular level
Time specificity No Controllable Promoter-dependent
Uncontrollable
Promoter context
Controllable
Induction process NA Extremely complicated
Tissue limitation
NA Required (but not
complicated)
Induction efficiency Excellent Low Promoter-dependent
Relatively high
Promoter-dependent
Difficult to achieve high
efficiency
Homogeneity of tumors Relatively consistent High variability
Skill-dependent
Low variability Low variability
Skill-dependent
Acquisition of the number
of mice
Easy Difficult Easy Manageable (but requires
induction process)
Maintenance of mouse
strains
Generally easy (dependent
on target genes; difficult
in the case of tumor
generation in
heterozygous mice)
Easy Complicated to maintain
animals having multiple
mutant alleles
Complicated to maintain
animals having multiple
mutant alleles
This table summarizes the advantages and potential problems in various types of genetically engineered mouse models for use in preclinical
studies of oncology drugs. NA, not applicable.
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Table 3. Mouse models corresponding to genetic mutations in human cancers
Human disease Mouse model
Cancer type
Mutated
gene
Mutated gene Mutation type
Mutation
induction
Tumor produced
Medulloblastoma RB1 Rb1/Tp53 Conditional KO ⁄ conditional KO GFAP-Cre Medulloblastoma(18)
Rb1/Bmi1 Conditional KO ⁄ conditional activation GFAP-Cre Medulloblastoma(19)
PTCH1 Ptch1 Conditional KO math1-cre ⁄
GFAP-Cre
Medulloblastoma(20)
Gorlin syndrome PTCH1 Ptch1 Conventional Medulloblastoma,
rhabdomyosarcoma(21)
Pituitary gland tumor RB1 Rb1 Conventional KO Pituitary gland tumor(22,23)
Rb1 Conditional KO Pomc-Flp Pituitary gland tumor(24)
Lung cancer KRAS Kras Conventional KO (sporadic activation) Lung cancer(25)
BRAF Braf Conditional activation Adex-Cre Lung cancer(26,27)
RB1 Rb1/Tp53/Pten Conditional KO ⁄ conditional KO ⁄
conditional KO
CGRP-CreER Lung cancer(28)
EML4-ALK EML4-ALK Conventional activation (SPC promoter) Lung cancer(29)
EML4-ALK Conditional activation Tet system Lung cancer(30)
KIF5B-RET KIF5B-RET Conventional activation (SPC promoter) Lung cancer(31)
EZR-ROS1 EZR-ROS1 Conventional activation (SPC promoter) Lung cancer(32)
Breast cancer PIK3CA Pik3ca Conditional activation MMTV-Cre Breast cancer(33)
TRP53 Pik3ca/Tp53 Conditional activation ⁄ conditional KO MMTV-Cre Breast cancer, leukemia(34)
PTEN Pten Conditional KO (stromal fibroblast) Fsp-Cre Breast cancer(35)
ERBB2 ErbB2 Conventional activation (MMTV promoter) Breast cancer(36,37)
ErbB2/Pten Conditional activation ⁄ conventional KO MMTV-Cre Breast cancer(38)
RB1 Rb1/Tp53 Conditional KO ⁄ conditional KO MMTV-Cre Breast cancer(39)
Hereditary breast
cancer
BRCA1 Brca1/Tp53 Conditional KO ⁄ conventional KO BLG-Cre Breast cancer(40)
Brca1/Chk2 Conditional KO ⁄ conventional KO Wap-Cre Breast cancer(41)
BRCA2 Brca2/Tp53 Conditional KO ⁄ conventional KO K14-Cre Breast cancer, skin tumor(42)
Colorectal cancer APC Apc/Kras Conditional KO ⁄ conditional activation Adex-Cre Colorectal cancer(43)
KRAS Apc/Kras Conditional KO ⁄ conditional activation Fapbl-Cre Colorectal cancer(44)
PTEN Apc/Pten Conditional KO ⁄ conditional KO Cyp1a1-
CreERT2
Tumor of the digestive tract(45)
Smad4 Apc/Smad4 Conventional KO ⁄ conventional KO Tumor of the digestive tract(46)
Familial adenomatous
polyposis
APC Apc Conventional KO Tumor of the digestive
tract(47–49)
Apc Conditional KO Adex-Cre Tumor of the digestive
tract,(50) liver cancer(51)
Hereditary non-
polyposis
colorectal cancer
MSH3 Msh3 Conventional KO Lymphoma(52)
MSH6 Msh6 Conventional KO Lymphoma,(52) tumor of the
digestive tract, skin cancer,
uterine cancer(53)
Msh3/Msh6 Conventional KO Lymphoma,(52) tumor of the
digestive tract,(54) skin
tumor(53)
Cowden syndrome PTEN Pten Conventional KO Tumor of the digestive tract,
lymphoma, adrenal tumor,
breast cancer, prostate
cancer(55,56)
Pancreatic cancer KRAS Kras/Tp53 Conditional activation ⁄ conditional KO pdx1-cre Pancreatic cancer(57)
Kras/Tgfbr2 Conditional activation ⁄ conditional KO Ptf1a-cre Pancreatic cancer(58)
Kras/Pten Conditional activation ⁄ conditional KO pdx1-cre Pancreatic cancer(59)
Endometrial cancer PTEN Pten/Mig6 Conditional KO ⁄ conditional KO PR-Cre Endometrial cancer(60)
Pten/Tp53 Conditional KO ⁄ conditional KO PR-Cre Endometrial cancer(61)
Ovarian cancer KRAS Kras/Pten Conditional activation ⁄ conditional KO Adex-Cre Ovarian cancer(62)
APC Apc Conditional KO Pgr-Cre Ovarian cancer(63)
BRCA2 Brca2/Tp53 Conditional KO ⁄ conventional KO K18-Cre Ovarian cancer(64)
Prostate cancer BRCA2 Brca2/Tp53 Conditional KO ⁄ conventional KO Pbsn-Cre Prostate cancer(65)
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cies of those kinase inhibitors, transplantation models with tar-
get (mutant) gene-positive cancer cells or GEM models driven
by target (mutant) genes have been generally used. In general,
cancer cells that have potent driver gene mutations (“gain-of-
function” mutations) show a high degree of so-called oncogene
addiction, and therefore it would be relatively easy to predict
or evaluate the drug response in vivo. These
non-clinical cancer models are also useful for evaluating phar-
macodynamics of the drugs by monitoring the phosphorylation
status of the target molecules, their downstream factors, or both.
Meanwhile, it should also be noted that established cancer cell
lines may have altered their phenotypes and characters compared
with the original cancers during in vitro culture, whereas geneti-
cally engineered cell lines may not be able to accurately
replicate the etiology of the relevant clinical cancer types.
Multitargeted kinase inhibitors. Multitargeted kinase inhibi-
tors include a RAF ⁄vascular endothelial growth factor recep-
tor-2 (VEGFR-2) ⁄PDGFR-b inhibitor (sorafenib), a VEGFR2
⁄PDGFR-b ⁄KIT ⁄FLT-3 inhibitor (sunitinib), a VEGFR ⁄KIT
⁄PDGFR inhibitor (pazopanib), a RET ⁄VEGFR2 ⁄EGFR inhibi-
tor (vandetanib), a VEGF ⁄PDGF inhibitor (axitinib), a
VEGFR ⁄RET ⁄KIT ⁄PDGFR ⁄RAF inhibitor (regorafenib), a
MET ⁄RET ⁄VEGFR ⁄KIT ⁄FLT-3 ⁄TIE-2 ⁄TRKB ⁄AXL inhibitor
(cabozantinib), and a VEGFR ⁄FGFR ⁄PDGFR ⁄SRC ⁄LCK
⁄LYN ⁄FLT-3 inhibitor (nintedanib). Similarly to TKIs, the effi-
cacy of MTKIs can be evaluated in non-clinical cancer mod-
els. However, MTKIs target multiple kinases and it is
generally difficult to prepare genetically engineered cell lines
that reproduce the pathology of the target cancers. In the case
of MTKIs that target angiogenic factors, such as VEGFR,
FGFR, and PDGFR, accurate prediction of in vitro efficacy
would be difficult: pazopanib, for example, does not necessar-
ily show a direct antiproliferative effect on many cancer cell
lines in vitro, but it significantly inhibits tumor growth in vivo
by blocking angiogenesis.(74) Also, because MTKIs could have
multiple modes of action, establishment of the proof-of-con-
cept at the pharmacodynamic level in non-clinical cancer mod-
els might require a complex procedure.
Targeting cell cycle. Palbociclib inhibits cyclin-dependent
kinases 4 and 6 (CDK4 and CDK6), which are involved in cell
cycle control. Furthermore, drugs targeting various cell cycle
regulators, such as WEE1, cell division cycle 7, checkpoint
kinase 1 and 2, ATR, Aurora, PLK, and mitotic kinesins, are
under clinical development. Efficacies of these drugs can be
evaluated using relevant cancer cell lines that have abnormali-
ties in the target molecules or their regulators (e.g. CCND1
⁄CDK6 amplification or CDKN2 deletion ⁄mutation) in trans-
plantation models.
Targeting protein degradation systems. Protein degradation
systems have been recognized as an emerging therapeutic
target for particular types of cancer. While several target mole-
cules have been described in this category, proteasome inhibi-
tors, such as bortezomib and carfilzomib, have been developed
most extensively and approved as anticancer drugs. Mean-
while, other molecular targets include the NEDD8-activating
enzyme, the ubiquitin-activating enzyme, and stress proteins
that are involved in protein folding, such as heat shock protein
90 and glucose-regulated protein 78. Given that the preferen-
tial efficacies of proteasome inhibitors against multiple mye-
loma have been well established, transplantation models with
multiple myeloma cell lines could be applicable for evaluating
the efficacy of the drugs in this category. However, there are
several potential issues and limitations for predicting the clini-
cal efficacy of these drugs from non-clinical cancer models:
detailed mechanisms for the action of the drugs and predictive
biomarkers for the drug responses are rather elusive, and can-
cer types that are susceptible to the anticancer effects of the
drugs in non-clinical studies may not be consistent with those
in the clinical settings. Therefore, the latest knowledge from
basic research and clinical phase I studies on various cancer
types should be taken into consideration for additional indica-
tion of the drugs.
Targeting genomes and epigenomes. The anticancer efficacies
of drugs that target cancer epigenomes, such as DNA methyl-
transferase inhibitors (azacytidine and decitabine) and histone
deacetylase (HDAC) inhibitors (vorinostat, panobinostat, romi-
depsin, and belinostat), have been shown in vivo, although the
cancer types against which the drugs are effective differ
between the non-clinical studies and clinical practice in some
cases.(84) As these drugs affect many target sites in a genome-
wide manner, detailed mechanisms and predictive biomarkers
for the drug response often remain elusive. Drugs targeting the
genomic repair systems include poly(ADP-ribose) polymerase
(PARP) inhibitors, such as olaparib. Because there is a syn-
thetic lethal relationship between PARP and tumor suppressors,
BRCA1 and 2, It would be relatively easy to predict the thera-
peutic efficacy of PARP inhibitors by using transplant models
of cell lines with BRCA1 or 2 deficiency.(85,86) Besides
BRCA1 ⁄2, it has been also postulated that there are many syn-
thetic lethal factors with PARP inhibition. However, the clini-
cal validity of those candidates has not been fully established.
However, it should be also noted that synthetic lethality con-
firmed in the non-clinical studies (e.g. effect of a PARP inhibi-
tor on EWS-FLI1-positive Ewing’s sarcoma)(87,89) could be
sometimes abolished by the formerly applied therapies in the
clinical settings.
Targeting cancer cell metabolisms. Metabolic enzymes
favored by cancer cells, such as isocitrate dehydrogenases 1 ⁄2
(IDH1 ⁄2) and fatty acid synthase, are potential targets for can-
cer therapy. For IDH1 ⁄2 inhibitors, transplant models of IDH1
Table 3 (Continued)
Human disease Mouse model
Cancer type
Mutated
gene
Mutated gene Mutation type
Mutation
induction
Tumor produced
Skin tumor BRAF Braf Conditional activation Tyr-CreERT2 Malignant melanoma(66)
Braf/Pten Conditional activation ⁄ conditional KO Tyr-CreERT2 Malignant melanoma(67)
PTCH1 Ptch1 Conditional KO R26-CreERT2 Basal cell tumor(20)
Mouse models reproducing generative tissues and mutations found in human caner. While many other scientifically excellent mouse models for
human cancers have been generated, the table preferentially lists those harboring relatively simple mutant alleles suitable for preclinical studies.
It should be noted some mouse models do not completely recapitulate pathologies of human cancer.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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(R132) or IDH2(R172) mutation-positive AML and glioma cell
lines are useful for predicting drug efficacies.(88) The
pharmacodynamics of these drugs can be evaluated by moni-
toring the mutation-specific metabolite (oncometabolite), 2-
hydroxyglutaric acid. However, if the target molecule does not
produce a characteristic oncometabolite, one may expect a
broader spectrum of anticancer efficacies of the inhibitors. In
that case, however, it may be relatively difficult to evaluate
Table 5. Evaluations of drugs targeting angiogenesis and tumor stroma
Classification Target
Evaluation method (drug
efficacy study)
Characteristics Problems
Targeting
angiogenesis
Angiogenic factors
(ligands)
e.g. VEGF antibody
(i) Mouse cancer models
(ii) Human cancer models
(iii) Angiogenesis models
(e.g. Matrigel plug assay,
CAM assay, hollow fiber
assay)
Evaluate in mouse ⁄ human
cancer transplantation
models with drugs and
targets exhibit cross-
reactivity between species
Mechanisms of action can
be examined depending
on phenotypes of target
molecule deficiency in
GEM models
(i) Mouse transplantation models,
GEM models
(ii) Human cancer models: Cross-
reactivity of the target molecule in
mice should be considered
(iii) Angiogenesis models: Consider
the cross-reactivity of the drug
between species. Generally difficult
to evaluate drug efficacy in
chemical carcinogen-induced
models
Receptors ⁄ receptor signals
e.g. TKI (VEGFRs)
As above, (i), (ii), and (iii) (i) Mouse transplantation
models
(ii) Human cancer models
(cell line transplantation,
PDX): The effect of the
drug on mouse
angiogenesis can be
evaluated
Mechanisms of action can
be examined depending
on phenotypes of target
molecule deficiency in
GEM models
As above, (i) and (ii).
Production of
angiogenesis factors
e.g. mTOR inhibitor
As above, (i), (ii), and (iii) (i) Mouse transplantation
models
(ii) Human cancer models
(cell line transplantation,
PDX): The effect of the
drug on mouse
angiogenesis can be
evaluated.
Mechanisms of action can
be examined depending
on phenotypes of target
molecule deficiency in
GEM models.
(i) Mouse transplantation models,
GEM models: Consider the cross-
reactivity of the drug between
species.
(ii) Human cancer models: Cross-
reactivity of the target molecule in
mice should be considered
(iii) Angiogenesis models: Difficult to
evaluate drug efficacy due to the
lack of angiogenesis factor
production
Targeting tumor
stroma
Drug resistance ⁄ sensitivity,
growth ⁄ metastasis,
inflammation
(i) Mouse ⁄ human cancer
transplantation model
(s.c. transplantation
models, orthotopic
transplantation
⁄ metastasis models),
cancer cell–stromal cell
co-transplantation models
(ii) GEM models
(i) Evaluate in mouse
⁄ human cancer
transplantation models
with drugs and targets
exhibit cross-reactivity
between species
(ii) Mechanisms of action
can be examined
depending on
phenotypes of target
molecule deficiency in
GEM models
(i) Transplantation models: Consider
the cross-reactivity of the drug
(mouse) or target (human). Human
cancer s.c. transplantation models:
Difficult to evaluate drug efficacy
due to insufficient involvement of
microenvironments
(ii) GEM models: Cross-reactivity of
the target molecule in mice should
be considered. Generally difficult to
evaluate drug efficacy in chemical
carcinogen-induced models
Animal (mainly mouse) models used for the evaluation of oncology drugs targeting angiogenesis and tumor stroma are classified in this table.
As the efficacy of these drugs depends on cancer–host interactions or host factors, consideration should be given to the cross-reactivity of thera-
peutic drugs and ⁄ or their target molecules between species (mainly between humans and mice). CAM, chick chorioallantoic membrane; GEM,
gene-engineered mouse; mTOR, mammalian target of rapamycin; PDX, patient-derived xenograft; TKI, tyrosine kinase inhibitor; VEGF, vascular
endothelial growth factor; VEGFR, VEGF receptor.
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the efficacy of the drugs because the mechanism of action and
predictive biomarkers would remain unclear.
Targeting Cancer Cell–Host Interactions
The importance of microenvironments on the growth, progres-
sion, and therapeutic resistance of cancer cells has been drawn
much attention. Such tumor microenvironments have been
known to support cancer cell proliferation directly or indirectly
through interactions between surrounding stroma cells. In gen-
eral, it is relatively difficult to carry out an appropriate in vivo
efficacy test for drugs targeting interactions between cancer
cell and host microenvironment in non-clinical cancer models.
Targeting angiogenesis. It has been widely recognized that
generation of new blood vessels into tumor (angiogenesis) is a
critical step for cancer cells to be adequately supplied nutrition
and oxygen, therefore, it is assumed that tumors are unable to
grow progressively without angiogenesis. There are also sev-
eral relevant studies suggesting that angiogenesis is involved
in not only cancer cell proliferation but also cancer cell pro-
gression, including metastases to distant organs. As represented
by VEGF inhibitors (bevacizumab), drugs targeting angiogene-
sis may not exert direct antitumor effects on cancer cells, how-
ever, should inhibit the activity of various angiogenic factors
that mainly affect vascular endothelial cells for generating new
blood vessels. Consequently, non-clinical evaluation of the
efficacy of drugs targeting angiogenesis can be greatly affected
by host factors in experimental animals; therefore, it is critical
to use appropriate models for drug evaluation, as summarized
in Table 5.
For carrying out appropriate in vivo tests for drugs targeting
angiogenesis, it is very important to consider whether cancer
cell lines or patient-derived samples produce angiogenic
factors for targeting and, moreover, their cross-reactivity in
non-clinical cancer models. It is also relevant for other angio-
genesis models such as the Matrigel plug assay, chick
chorioallantoic membrane assay, or hollow fiber assay.
Targeting cancer stroma. Diverse cellular components of
tumor stroma (e.g. fibroblasts, mesenchymal cells, and inflam-
matory cells) and extracellular matrices (e.g. fibronectin, colla-
gen, laminin, and proteoglycan) have been shown to be
involved in cancer cell proliferation and progression. Although
tumor stroma is expected to be an attractive therapeutic target,
the development of drugs targeting cancer stroma is still in the
early stages.
Similar to those targeting angiogenesis, non-clinical evalua-
tion of drugs targeting tumor stroma should be greatly affected
by host factors. In immune-compromised mice (e.g. nude,
SCID, NOD ⁄SCID, and NOG) often used for transplantation
models of human cancer cells display a range of different
Table 6. Evaluations of drugs targeting host immune response
Model Outline Characteristics Problems
Allograft model Syngeneic (mainly mouse) cancer cell
lines implanted into s.c. as
heterotopic transplantation models,
or implanted into original tissues
⁄ organs in orthotopic
transplantation models, or injected
into tail vein as metastasis models
Use of cell lines with ectopic
expression of model antigens (e.g.
OVA,(90,91) HA,(92) CEA(93)) or cell
lines known with their
immunogenicity (e.g. B16
melanoma,(94) Meth A,(95) colon
26(96))
Immune responses against cancer cells
can be monitored over time and the
mechanism of action can be tested
Tumor antigen-specific immune
responses can be evaluated where
antigens have been specified
Orthotopic transplantation models and
metastasis models may be better for
analyzing tumor-infiltrating
lymphocytes considering the organ
microenvironment of cancer cells.
Heterotopic transplantation models may
not immunologically completely reproduce
human cancer tissues due to insufficient
tumor stroma
Orthotopic ⁄ metastasis models require
technical skills and are generally difficult
for quantitative monitoring of tumor
growth.
Carcinogen-
induced mouse
model
Mouse models developing tumors by
challenging with carcinogenic
substances (e.g. MCA, AOM ⁄ DSS,
DMBA ⁄ TPA), or external stimuli
such as UV, or inducing genetic
abnormalities (e.g. p53 deficiency,
transduction of SV40T antigen, APC
deficiency)
Immune response during the
carcinogenic process can be evaluated
The clinical cancer pathology is closely
represented.
Requires complicated procedure and poses
difficulty in maintaining mouse strains
Longer experimental period
Difficult to evaluate antigen-specific
immune response due to the lack of
defined tumor antigens with some
exceptions
Xenograft
(human cancer)
model (includes
PDX)
Xenograft with human cell lines or
patient-derived tumor tissues into
immune-compromised mice (e.g.
nude mice, SCID mice, NOG mice).
Antitumor activities can be analyzed by
using human (cancer patients’) immune
cells.
Limitation for analyzing immune responses
due to its incompetence of the intact
immune system
Application of humanized mice engrafted
with human immune cells clearly requires
further investigation
Animal (mainly mouse) models used for evaluating drugs targeting host immune response are classified in this table. As the efficacy of cancer
immunotherapy depends on the host’s immune system, concurrent use of multiple models should also be considered. In such a case, it is neces-
sary to devise optimal combinations of models to be used, taking into account the potential limitations ⁄ problems of each model presented in
the table as advantages or disadvantages. AOM, azoxymethane; APC, Adenomatous polyposis coli; CEA, carcinoembryonic antigen; DMBA, 7,12-
dimethylbenz(a)anthracene; DSS, Dextran sulfate sodium; HA, hemagglutinin; MCA, 3-Methylcholanthrene; OVA, ovalbumin; PDX, patient-
derived xenograft; TPA, 12-O-TetradecanoyI-phorbol-13-acetate.
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immunological environments. Even in these immune-compro-
mised animals, myeloid compartment and mesenchymal cells
are known as relatively normal, therefore the efficacy of drugs
targeting those stromal cells may be evaluated even in animal
models if the target shows cross-reactivity between species.
Targeting host immune responses. The immune system has
been regarded as an important constituent of the tumor
microenvironment. Many series of studies have been under-
taken to understand the regulatory mechanisms by which can-
cer cells control, either positively or negatively, hosts’ immune
responses. Recent clinical successes of immune checkpoint
inhibitors, such as anti-CTLA-4 mAbs (ipilimumab and treme-
limumab) and anti-PD-1 mAbs (nivolumab and pem-
brolizumab) highlight targeting hosts’ immune responses
against cancer cells as a promising target for drug develop-
ment.
Obviously, drugs targeting hosts’ immune responses should
be tested in the appropriate non-clinical cancer models in
which the targets are involved in the immune responses against
cancer cells, for elucidating the mechanisms of action and pre-
dicting potential side-effects. In general, it is ideal to test the
importance of drug targets or potential drug candidates in dif-
ferent experimental models (multiple cell lines, different
mouse strains). Considering there should be a limitation for
predicting cancer types to which the drug shows clinical bene-
fit by testing only in non-clinical models, the results of phase I
clinical studies need to be carefully considered. For testing
drug candidates in which certain HLA haplotypes are required
to show antitumor effects (e.g. cancer vaccine therapy), an
application of humanized mice may be worth considering as
non-clinical models. In Table 6, we summarize pros and cons
of non-clinical models for testing drugs targeting hosts’
immune responses.
Evaluation of Oncology Drugs Based on New Concepts
Along with gaining our knowledge with the biological charac-
teristics of cancer, there are several new approaches to develop
oncology drugs, such as targeting cancer stem cells.
Targeting cancer stem cells. The concept of cancer stem cells
was originally introduced in hematological malignancies and
further extended to solid cancers such as breast cancer and
brain tumors.(97) Cancer stem cells have been characterized by
their self-renewal potential, multidirectional differentiation
potential, and niche dependence, similar to other stem cells, in
addition to their highly tumorigenic potential. Furthermore,
cancer stem cells have been known for their resistance to con-
ventional chemotherapy or radiotherapy; therefore, they may
be an emerging target for drug development. In Table 7, we
summarize the current methods for testing drugs targeting can-
cer stem cells in non-clinical evaluations.
Targeting other novel concepts or methods. In Table 8, we
summarize the current status of oncology drug development
targeting new concepts other than cancer stem cells, or novel
methods for developing new oncology drugs. Non-clinical
evaluation of some of those oncology drugs targeting novel
Table 7. Evaluation of drugs targeting cancer stem cells
Evaluation method Outline Characteristics Problems
Spheroid formation
potential
Culture a single non-adherent cell in
the presence of specific growth
factors (without serum) to test the
capability of forming spheroids
Evaluation can be made using cultured cells,
and the dose- and time-dependence can be
quantitatively measured
General cytotoxicity of
drugs mislead as positive
without testing on
normal tissue stem cells
Cell surface marker Measuring the frequency of CD44
high ⁄ CD24 low fraction, known as
cancer stem cells in breast cancer by
flow cytometry
Cytotoxic drugs can be tested by comparing
effect on cancer stem cell fraction and others
Surface markers for cancer
stem cell fractions differ
depending on cancer
types
ALDH ALDH activities positively correlate
to chemoresistance and stemness in
breast cancer, gastrointestinal tract
cancer, and hematological tumors
Established methods for measuring activity by
flow cytometry
Not all ALDH-positive cells
are cancer stem cells
Xenograft models with
human cancer stem cells
in immune-compromised
mouse
Human cancer stem cells
transplanted into immune-
compromised mice for testing drug
efficacy on tumor formation
⁄ growth
Evaluating the inhibitory effect of drugs on
tumor formation or growth and cancer stem
cell frequency within tumor tissue (assessed
based on surface markers, ALDH, and
spheroid formation potential)
Not applicable for testing
drugs targeting immune
responses or
microenvironments
Syngeneic mouse models
with mouse cancer stem
cells
Mouse cancer stem cells transplanted
into syngeneic mice for testing
drug efficacy on tumor formation
⁄ growth
Evaluating the inhibitory effect of drugs on
tumor formation or growth and cancer stem
cell frequency within tumor tissue (assessed
based on surface markers, ALDH, and
spheroid formation potential)
Applicable for testing drugs targeting immune
responses or microenvironments
Efficacy may need to be
confirmed in models
using human cancer stem
cells
Genetically engineered
animal models
Testing drugs targeting cancer stem
cells using genetically engineered
mice, rats, or zebrafish to develop
tumors
Ideal models closely resembles an
autochthonous tumor
Evaluation requires a
prolonged time period
because of late onset of
cancer compared with
transplantation models
This table lists commonly used methods to evaluate cancer stem cell functions. ALDH, aldehyde dehydrogenase.
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concepts may require approaches that are different from those
used for the evaluation of conventional oncology drugs.
A deeper understanding of the biological characteristics of
cancer is leading to the development of novel oncology drugs
based on new concepts such as “cancer stem cells” in addition
to the developmental targets presented in earlier sections.
Concluding Remarks
This review summarizes present non-clinical investigations by
listing the common methods currently used for the develop-
ment of oncology drugs as extensively as possible. Their types,
profiles, and problems are briefly described. Characteristics of
a variety of animal models, which provide indispensable infor-
mation to formulate clinical research and clinical trials, are
summarized according to each category of oncology drug.
Experimental models obtain the proof of evidence at the
molecular, cellular, and tissue levels, and unique oncology
drugs are also covered. It is hoped that this review provides
information to undertake regulatory science relevant to the
development of oncology drugs.
Studies with cancer models, including animal experiments,
ex vivo studies, and in vitro studies, are essential technology in
cancer biology and have contributed to the development and
evaluation of oncology drugs. Particularly, cancer cell lines
derived from humans and experimental animals have been
used for decades as indispensable tools for the biological
understanding of cancer and for the development of oncology
drugs. Properties of cancer cells represented by a cell have
been changing cell line, it was discovered that the accumula-
tion of multiple abnormalities in genes causes cancer and that
the properties of individual cancer cell lines depend not only
on their organ origins but also on the types of abnormal genes.
Growing knowledge on cancer as a disease has led to the
understanding that interactions between cancer and host cells
and the regulatory molecules play critical roles. The growth of
tumors strongly depends on tissue microenvironments and
immunological milieu that are difficult to reproduce in vitro.
As shown in this review, a substantial number of models
reflecting these various aspects of cancer–host interactions
have been developed in the past decade. These models have
significantly contributed to the expansion of the range of non-
clinical studies and their role, in the exploration, development,
and clinical investigation of oncology drugs have become
indispensable.
The diversity and the degree of engagement in genetic
changes in the initiation of cancer cell growth and progression
are widely accepted. The roles of host cells, tissue, and the
immune system also vary depending on the type, properties,
and the stage of individual tumors are also becoming clear
than before. Therefore, the methods used to select and use
oncology drugs should continuously be revised based on the
Table 8. Emerging new concepts in oncology drug development
Example Outline Problems
International comparison (e.g. clinical study
information)
Nucleic acid
medicine
Chemically synthesized
oligonucleotide
Need to consider appropriate DDS for
tumor targeting, efficiency for cellular
uptake, organ accumulation such as
liver
Japan: Phase I
Overseas: Phase I–III (sponsored by
OncoGenex Pharmaceuticals Inc., etc.)
Oncolytic virus Modified viruses reacting
specifically against tumors
Requirement for support system of
clinical studies ⁄ international joint
research, review system, guideline
establishment, and research funds
Japan: Phase I–II
Overseas: Approved (China); phase I–III
(USA and Europe)
Cell therapy Regenerative therapy using iPS
cells or immune cell therapy
Tumor development risk
Accumulation of evidence for
therapeutic efficacies
Japan: Phase I–II
Overseas: Approved (USA); phase I–III
Nanotechnology-
based drugs
Application to DDS; treatment
using microscopic particles
(embolization therapy)
Safety concerns by using nano-materials
Tumor-specific delivery
Japan: Phase I–III
Overseas: Approved; phase I–III
Companion
diagnostic drugs
Diagnostic drugs to evaluate the
efficacy and safety of specific
drugs
Not fully available for all
pharmaceutical products
Appropriate review system
Not fully clear for applying medical
service payment system
Japan: ALK fusion gene, KRAS gene
mutations, etc.
Overseas: BRAF gene mutations, and many
others
Hyperthermia Delivery of antineoplastic agents
to a tumor by heat
Safety concerns by using nano-materials Japan: Phase I–II
Overseas: Phase I–III
Imaging-based
therapy
Specific labeling of cancer cells;
effective for evaluation of
treatment effects
Not applicable to all cancer types
Requirement for efficacy ⁄ safety
verification
Japan: Under development
Overseas: Practical use in assessment of the
effect of cell transplantation therapy
Cancer cell line
panel†
Assessment of mechanisms of
action of candidate molecules
using a set of diverse cell types
Limited number of cell lines (potential
expansion)
Distinct nature from actual human
tumor samples
Japan: Panel of human cancer cell lines
(JFCR39)
Overseas: NCI-60 cell lines (NCI ⁄ NIH, USA);
ATCC tumor cell panels (USA); OncolinesTM
cancer cell line panel contains 66 cancer
cell lines (NTRC, Netherlands)
This table exclusively presents oncology drugs that are being or about to be investigated in Japan and overseas based on new concepts.
†Although “Cancer cell line panel” cannot be classified as a therapeutic drug, it is presented here as an assay that is extensively used in the
development of new therapeutic drugs. DDS, drug delivery system; iPS, induced pluripotent stem cells.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | February 2016 | vol. 107 | no. 2 | 200
Report
Non-clinical studies for oncology drug development www.wileyonlinelibrary.com/journal/cas
advance in understanding of cancer. As stated earlier in this
review, models established for the biological understanding of
cancer have proven to be useful as tools for non-clinical inves-
tigations. When developing a new drug that is in the same
class as those for which efficacy and safety information was
already acquired from clinical studies, it is also useful to select
non-clinical models based on the clinical information. Collec-
tively, it will become increasingly important to design, to
select, and to use appropriate non-clinical models in order to
design clinical research and trials. Investigations with these
models should be effective in interpreting the results of such
investigations and to re-evaluate the effects of oncology drugs
used in clinical practice. It is strongly hoped that non-clinical
investigation will continuously be successfully used for the
development, approval, and proper use of oncology drugs,
which accelerate drug development.
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